a genome company with POTENTIAL...-g-
float of just over 6 million..this one can move in chunks...
HYSQ
They have conferences coming up that most likely will be viewed very positively...look at recent presentations by INCY, etc...for charts and their moves.
hyseq.com
Peruse the news below and you will see that they have a strong footing in the gene sector, has great technology in biochip that can be of great advantage, and has the appropriate leadership that has led other companies like CRA, MLNM, and INCY to fly.
biz.yahoo.com
Tuesday February 15, 6:34 pm Eastern Time
Hyseq shares soar after biochip patent
issued
LOS ANGELES, Feb. 15 (Reuters) - Shares of Hyseq Inc.
(NasdaqNM:HYSQ - news) rose sharply on Tuesday after the
early-stage drug development company said it was issued a U.S.
patent on its method for confining and mixing DNA samples on chips using an electrical field.
Shares of Sunnyvale, Calif.-based Hyseq were up 12-1/4, or 17.5 percent, at 82-1/2 in late trading on
Nasdaq.
``This new patent gives us the advantage of using electronics for more precise confinement and
manipulation of DNA samples and probes on chips,' Dr. Radoje Drmanac, Hyseq's chief scientific
officer, said in a statement.
biz.yahoo.com
Wednesday February 2, 7:59 am Eastern Time
Company Press Release
SOURCE: Hyseq, Inc.
Dr. George B. Rathmann Joins Hyseq
as Chairman
Biotechnology Industry Pioneer and Leader Previously was Chairman of
Amgen and ICOS
SUNNYVALE, Calif., Feb. 2 /PRNewswire/ -- Hyseq, Inc. (Nasdaq: HYSQ - news) announced
today that Dr. George B. Rathmann has joined Hyseq as Chairman. Dr. Rathmann has been a leading
figure in biotechnology for over 20 years, as co- founder and Chairman of Amgen, Inc., and more
recently of ICOS Corporation. Robert D. Weist, who has served as Chairman of Hyseq since 1994,
becomes Vice Chairman.
``I have had the good fortune to be part of the biotechnology industry since its inception,' said Dr.
Rathmann. ``Genomics now is providing an unprecedented wealth of opportunities for new drugs.
Hyseq is building a highly promising biopharmaceutical pipeline, using genomics as a foundation. I have
had a longstanding interest in the company and I look forward to helping Hyseq realize the potential in
its products and technology,' said Dr. Rathmann.
``This is an excellent opportunity for the company and I am looking forward to being part of it,' said
Robert D. Weist, former Chairman of Hyseq's Board, and now Vice Chairman. ``George's experience,
energy and enthusiasm, will add significant value to the company. As a mentor, George has no peers,'
said Mr. Weist.
biz.yahoo.com
Friday January 28, 10:04 am Eastern Time
Company Press Release
SOURCE: Hyseq, Inc.
Hyseq Awarded Patent on Sets of
Overlapping Probes Used in DNA
Analysis; New Patent Covers Probe Sets Used for Many
Biochips
SUNNYVALE, Calif., Jan. 28 /PRNewswire/ -- Hyseq, Inc. (Nasdaq: HYSQ - news) announced
today that it was issued United States Patent No. 6,018,041 (the '041 patent) which covers sets of
probes of known sequence, any subset of which overlaps along a sample. This type of probe set is
used for many biochips.
``This new patent is another example of the breadth of Hyseq's core sequencing by hybridization
(SBH) patents, the first of which issued in 1993. Our new patent extends our intellectual property
position to sets of overlapping probes, an important component of many biochips and other DNA
analysis tools used for gene sequencing, SNP or other polymorphism detection and gene expression
measurement,' said Dr. Radoje Drmanac, Hyseq's Chief Scientific Officer.
``We believe our patent portfolio now covers elements important to many biochips and their use. Our
core SBH patents cover methods of use. This new '041 patent covers a type of probe used on many
biochips. We also have filed patent applications on more than 900,000 partial and full length gene
sequences that can be used as content for biochips. We believe our patent coverage gives us a central
position in the biochip market,' said Lewis S. Gruber, Hyseq's President and Chief Executive Officer.
biz.yahoo.com
Wednesday January 12, 7:31 am Eastern Time
Company Press Release
SOURCE: Hyseq, Inc.
Hyseq Announces DNA Sequencing
Chip Breakthrough; More than 3,000
Bases of Any Gene Can Be Sequenced in a Single Reaction -
Major Advance in SNP Detection
SUNNYVALE, Calif., Jan. 12 /PRNewswire/ -- Hyseq, Inc. (Nasdaq: HYSQ - news) announced
today a major advance that allows its DNA sequencing chip to sequence more than 3,000 bases of any
gene in a single reaction. This read length is at least three times longer than produced by traditional
gel-based technologies, the only other technology capable of sequencing any gene without using a
specific reference gene or sequence. Because Hyseq's biochip reads every base, it is capable of
detecting all mutations in a single reaction. Other biochips in the market are designed for specific genes
and are not able to detect every possible single nucleotide polymorphism (SNP).
Hyseq believes that this new advance makes its biochip a powerful tool for large-scale SNP and other
polymorphism detection. Hyseq biochips, including those with this advanced technology, can be used in
off-the-shelf commercial readers.
``With this advance, we can use a single type of biochip to determine a sequence or to detect any
polymorphism,' said Radoje Drmanac, Hyseq's Chief Scientific Officer. ``We believe that our biochip's
ability to detect any of the millions of human SNPs will make it an important tool in pharmacogenomics
and for diagnostic use in personalized medicine. Because our biochips can sequence any gene in long
reads, we believe our chip also will have great value in identifying specific microbial pathogens
associated with disease (such as E. coli) or with biological warfare,' added Dr. Drmanac.
biz.yahoo.com
Thursday January 6, 8:05 am Eastern Time
Company Press Release
SOURCE: Hyseq, Inc.
Hyseq Adds Over 5,000 Completely
Sequenced Novel Genes to its Portfolio
SUNNYVALE, Calif., Jan. 6 /PRNewswire/ -- Hyseq, Inc. (Nasdaq: HYSQ - news) announced
today that it has added more than 5,000 completely sequenced proprietary genes to its HyProfile(TM)
Portfolio, making it one of the largest of its kind in the world. Hyseq intends to pursue
commercialization of select gene product candidates internally and through licensing.
Of these 5,000 completely sequenced genes, Hyseq scientists have found that approximately 1,200
contain secretory signal peptide segments, and 3,800 have significant homology to known genes which
provides the basis for structural and functional analysis. The presence of secretory signal peptide
segments means these genes are capable of producing either proteins which are secreted into the blood
stream making them drug candidates, or membrane-bound proteins which are potential drug targets.
``Given the more than 12 million human DNA samples we have processed for our internal use, and the
depth to which we are able to mine tissues because of our proprietary technology, we believe that we
have one of the best pipelines for biopharmaceutical product candidates in the industry,' said Lewis S.
Gruber, Hyseq's President and Chief Executive Officer. ``Now that we are completing our
determination of human gene sequences, our strategy is to develop product candidates for treating
inflammatory and cardiovascular diseases while making others available for licensing. We are currently
progressing with pre-clinical studies on our IL-1Hy1 anti-inflammatory and CD39L4 anti-clotting drug
candidates,' said Mr. Gruber. |
